Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...

On the call, Okupe said Hims’ “steady state weight-loss offering” would be “primarily composed” of generic weight loss pills—not GLP-1 medicines—along with a generic version of an ...